A Phase Ib, Open-label, Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of PIT565 in Participants With Rheumatoid Arthritis (RA)
Latest Information Update: 08 Jul 2025
At a glance
- Drugs PIT 565 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 30 Jun 2025 Status changed from not yet recruiting to recruiting.
- 24 Jun 2025 New trial record